dipity

Recent Event Highlights: Updated FDA Action on Plan B (levonorgestrel) Tablets, Ardea Biosciences Finds Early Results of Drug Candidate Equivalent to Existing Gout Treatment, FDA Sends Letters to 14 Companies Regarding Internet Ads, Digoxin, USP 0.125 mg, Digoxin, USP 0.25 mg (Caraco brand), Cialis, Cymbalta Lead 2008’s Most Recalled Drug Ads, ULORIC(R) (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout, and 7 more...

Created by dipity on Apr 26, 2009

Last updated: 04/26/09 at 09:09 AM

• Updated FDA Action on Plan B (levonorgestrel) Tablets
  Apr 23, 2009 6:31 AM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/a_UQW6xDLi4/updated-fda-action-plan-b-levonorgestrel-tablets-17363.html

• Dietary Supplements Distributed by Universal ABC Beauty Supply International, Inc.
  Apr 21, 2009 9:00 PM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/xfn38vddXgo/dietary-supplements-distributed-universal-abc-beauty-supply-international-inc-12510.html

• Ardea Biosciences Finds Early Results of Drug Candidate Equivalent to Existing Gout Treatment
  Apr 20, 2009 4:20 PM

  Excerpt ...a 45 percent drop in uric acid levels after 10 days. The result was similar to what was seen in early stage studies of Uloric, Quart said. Ardea said no serious side effects were observed in its study. Quart said the relatively safety of the drug means it... Source Info Xconomy
  http://www.xconomy.com/san-diego/2009/04/20/ardea-biosciences-finds-early-results-of-drug-candidate-equivalent-to-existing-gout-treatment/

• Discontinuation of Development of AC-3933, Therapeutic Agent for Dementia
  Apr 17, 2009 7:54 AM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/bbV9CdjwBKw/discontinuation-development-ac-3933-therapeutic-agent-dementia-17267.html

• Influend Cough and Cold Products
  Apr 15, 2009 9:00 PM

  Excerpt ...Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/r2hKTpaq5Qo/influend-cough-cold-products-12509.html

• Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement
  Apr 7, 2009 1:16 PM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/TR76LtLHpYk/avalon-pharmaceuticals-receives-audit-opinion-containing-going-concern-statement-17100.html

• AMA Announces Staff Reductions
  Apr 7, 2009 8:50 AM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/7og0RH5YbOo/ama-announces-staff-reductions-17086.html

• FDA Sends Letters to 14 Companies Regarding Internet Ads
  Apr 6, 2009 8:44 AM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/u29Cv3s_tT8/fda-sends-letters-14-companies-regarding-internet-ads-17060.html

• Digoxin, USP 0.125 mg, Digoxin, USP 0.25 mg (Caraco brand)
  Apr 1, 2009 4:39 PM

  Excerpt ...drug zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/-tAnZdPs9yg/digoxin-usp-0-125-mg-digoxin-usp-0-25-mg-caraco-brand-12503.html

• Solvay Confirms It Is Proceeding With An Analysis Of Various Options For Its Pharmaceutical Activ...
  Apr 1, 2009 10:21 AM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/6MOcsm_TE5o/solvay-confirms-proceeding-analysis-various-options-pharmaceutical-activities-16992.html

• Cialis, Cymbalta Lead 2008’s Most Recalled Drug Ads
  Mar 31, 2009 2:55 PM

  Excerpt ...zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Uloric Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ATryn ATryn... Source Info Drugs.com
  http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/ofb3Id-BTR8/cialis-cymbalta-lead-2008-8217-s-most-recalled-ads-16974.html

• ULORIC(R) (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperu...
  Mar 12, 2009 12:02 PM

  Excerpt ...mg (50 percent) and ULORIC 80 mg (72 percent) versus allopurinol 300/200 mg (42 percent) (p
  http://www.streetinsider.com/Press+Releases/ULORIC%28R%29+%28febuxostat%29+40-mg+and+80-mg+Tablets+Now+Available+for+the+Chronic+Management+of+Hyperuricemia+in+Patients+with+Gout/4482009.html

• Author of 'Beating Gout: A Sufferer's Guide to Living Pain Free' Interviewed Part 1
  Feb 27, 2009 2:02 PM

  ... gout "beating gout" "stop gout" "gout pain" "gout treatment" arthritis febouxostat uloric allopurinol probenecid colchicine "gout beer" Konshin

• FDA OKs New Gout Drug Uloric
  Feb 17, 2009 12:54 PM

  Excerpt ...helps prevent uric acid production, lowering elevated uric acid levels, according to Takeda. In 2005, the FDA refused to approve Uloric because there were slightly more deaths and heart problems in patients taking the drug than in patients taking allopurinol,... Source Info MedicineNet Related Topics
  http://www.medicinenet.com/guide.asp?s=rss&k=DailyHealth&a=97798

• New Gout Drug Gets FDA Panel Nod
  Nov 24, 2008 2:31 PM

  Excerpt ...gout. The body converts a chemical called xanthine into uric acid via an enzyme called xanthine oxidase or XO. Allopurine and Uloric each inhibit XO and prevent the formation of uric acid. Allopurinol is approved in doses up to 800 milligrams. However, it's... Source Info WebMD
  http://www.webmd.com/news/20081124/new-gout-drug-gets-fda-panel-nod?src=RSS_PUBLIC